Antibody ID	ANI0CLWAZ
Antibody Name	Anti-STEAP2 mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1
Antigen Name	Metalloreductase STEAP2 (STEAP2)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.80%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 5 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 11.33 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 20 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 30 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 20 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 10 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.016 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 34% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.023 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 10% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.023 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 42% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.029 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 18% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.029 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 40% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.036 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 13% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 12% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 41% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 44% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.044 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 46% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.046 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 43% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.063 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 45% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.064 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 32% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.065 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 14% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.078 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 20% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.078 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 39% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.083 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 19% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.087 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 36% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 11% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.098 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 38% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.118 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 23% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.135 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 24% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.182 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 22% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.22 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 15% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.232 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 26% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.376 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 27% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.083 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 16% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.329 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 29% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.366 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 25% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.591 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 17% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.733 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 30% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.282 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 37% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	23.401 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 33% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	58.334 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 21% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	80.211 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 35% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	321.547 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 31% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	461.721 nM	Positive HER2 expression (HER2+++/++)
Method Description	The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 28% FBS,penicillin/streptomycin and L-glutamine.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Ref 1	Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof.
Ref 2	Tubulysins and protein-tubulysin conjugates